Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study.
نویسندگان
چکیده
OBJECTIVES To determine the risk of stroke associated with oral and transdermal routes of administration of hormone replacement therapy. DESIGN Population based nested case-control study. Setting About 400 general practices in the United Kingdom contributing to the General Practice Research Database. Participants Cohort of all women in the database aged 50-79 years between 1 January 1987 and 31 October 2006 who were members of a practice that fulfilled predefined quality criteria and without a diagnosis of stroke before cohort entry. For each case of stroke occurring during follow-up, up to four controls were selected from among the cohort members in the risk sets defined by the case. Exposure to hormone replacement therapy (HRT) was categorised into oestrogens only, oestrogens plus progestogen, progestogen only, and tibolone. Oestrogens were further subdivided according to the route of administration (oral v transdermal) and dose (high v low). Main outcome measures Rate ratio of stroke associated with current use of oral and transdermal HRT compared with no use. Current use was considered as a prescription whose duration included the index date. RESULTS There were 15,710 cases of stroke matched to 59 958 controls. The rate of stroke in the cohort was 2.85 per 1000 per year. The adjusted rate ratio of stroke associated with current use of transdermal HRT was 0.95 (95% CI 0.75 to 1.20) relative to no use. The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)). Current users of oral HRT had a higher rate of stroke than non-users (rate ratio 1.28 (1.15 to 1.42)) with both low dose and high dose. CONCLUSIONS The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.
منابع مشابه
Postmenopausal Hormone Therapy and Risk of Stroke
BACKGROUND AND PURPOSE The benefit/risk analysis of hormone therapy in postmenopausal women is not straightforward and depends on cardiovascular disease. Evidence supports the safety of transdermal estrogens and the importance of progestogens for thrombotic risk. However, the differential association of oral and transdermal estrogens with stroke remains poorly investigated. Furthermore, there a...
متن کاملHormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study.
BACKGROUND Epidemiological studies suggest a decreased risk of coronary heart disease (CHD) in healthy women taking hormonal replacement therapy (HRT). Whether this effect is shared by oral and transdermal preparations is unknown. METHODS AND RESULTS We conducted a population-based case-control study nested in a cohort of women 50 to 74 years of age without cardiovascular disease history in t...
متن کاملHormone replacement therapy: prothrombotic vs. protective effects.
Hormone replacement therapy (HRT) is associated with reduced risk of coronary heart disease (CHD) and stroke in observational studies; however the possibility of confounding by other risk factors requires prospective assessment of its risks and benefits in randomised controlled trials. The HERS trial of oral HRT in secondary CHD prevention observed an early increased risk of myocardial infarcti...
متن کاملPrevention and treatment of venous thromboembolism during HRT: current perspectives
Many large trials in the past 15 years have proven an increased risk of vascular complications in women using oral, mostly non-bioidentical, hormone therapy. The risk of vascular complications depends on the route of administration (oral versus transdermal), age, duration of administration, and type of hormones (bioidentical versus non-bioidentical). Acquired and/or hereditary thrombophilias (e...
متن کاملWhat's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone.
The original conclusions of the Women's Health Initiative study have been questioned as a result of the availability of age-stratified data. Initial concerns regarding the risk of coronary heart disease (CHD) in association with the use of hormone replacement therapy (HRT) have been replaced with concerns regarding thromboembolic disease, encompassing venous thromboembolism (VTE), particularly ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- BMJ
دوره 340 شماره
صفحات -
تاریخ انتشار 2010